论文部分内容阅读
目的系统评价白细胞介素6(IL-6)基因-174G/C多态性与慢性阻塞性肺疾病(COPD)发病风险的相关性。方法计算机检索PubMed、EMbase、CNKI、WanFang Data、CBM和VIP数据库有关IL-6基因-174G/C多态性与COPD发病风险的病例-对照研究,检索时限均为从建库至2013年6月。由2位研究者按纳入与排除标准独立筛选文献、提取资料后,采用RevMan 5.2软件进行Meta分析。结果最终纳入5个研究,共计487例COPD患者和786例对照。Meta分析结果显示IL-6基因-174G/C多态性和COPD发病风险无相关性:GC+CC vs.GG:OR=1.01,95%CI(0.76,1.34),P=0.95;CC vs.GC+GG:OR=1.04,95%CI(0.70,1.54),P=0.85;CC vs.GG:OR=1.05,95%CI(0.69,1.61),P=0.81;GC vs.GG:OR=1.00,95%CI(0.74,1.35),P=0.99;C vs.G:OR=1.02,95%CI(0.83,1.24),P=0.88。结论 IL-6基因-174G/C多态性可能不是COPD发病风险的危险因素。
Objective To systematically evaluate the association between IL-6 gene-174G / C polymorphism and the risk of developing chronic obstructive pulmonary disease (COPD). METHODS: A case-control study was performed using the PubMed, EMbase, CNKI, WanFang Data, CBM and VIP databases for the risk of IL-6 gene -174G / C polymorphism and COPD. The search time was from the database to June 2013 . Two researchers independently screened the documents according to inclusion and exclusion criteria. After extracting the data, Meta-analysis was performed using RevMan 5.2 software. Results Finally, 5 studies were included, for a total of 487 COPD patients and 786 controls. Meta-analysis showed no correlation between -174G / C polymorphism of IL-6 gene and the risk of COPD: GC + CC vs.GG: OR = 1.01,95% CI (0.76, 1.34), P = 0.95; GC + GG: OR = 1.04, 95% CI (0.70, 1.54), P = 0.85; CC vs.GG:OR=1.05,95%CI(0.69,1.61),P=0.81;GC vs.GG:OR= 1.00, 95% CI (0.74, 1.35), P = 0.99; C vs. G: OR = 1.02, 95% CI (0.83, 1.24), P = 0.88. Conclusion IL-6 gene-174G / C polymorphism may not be a risk factor for COPD risk.